Search
Alisertib
go.drugbank.com/drugs/DB05220InvestigationalAlisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.
Categories: Heterocyclic Compounds, 1-RingCobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalCobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: COTELLIC® (COBIMETINIB) 20 MG TABLETAS RECUBIERTASRonacaleret
go.drugbank.com/drugs/DB05255InvestigationalRonacaleret is a calcium-sensing receptor antagonist.
Dexlansoprazole
go.drugbank.com/drugs/DB05351ApprovedCompared to the older generation of PPIs (which includes [DB00213], [DB00338], and [DB00448]),[A178084] dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery … Dexlansoprazole is the R-enantiomer of [DB00448], which is composed of a racemic mixture of the R- and S-enantiomers.
Categories: Cytochrome P-450 Substrates, 2-PyridinylmethylsulfinylbenzimidazolesSynonyms: (+)-2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE, 1H-BENZIMIDAZOLE, 2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-Brivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalBrivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesProducts: BRIVIACT®10 MG, BRIRENTO® 100 MG TABLETASGantacurium
go.drugbank.com/drugs/DB05710InvestigationalGantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker. It is being developed by Avera Pharmaceuticals.
Categories: Heterocyclic Compounds, 2-RingDovitinib
go.drugbank.com/drugs/DB05928InvestigationalChiron currently has three ongoing Phase I clinical trials for dovitinib.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersCariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigational[A247100] It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. … Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N’,N’-dimethylurea hydrochlorideBradanicline
go.drugbank.com/drugs/DB06090InvestigationalBradanicline belongs to a new class of drugs for the treatment of central nervous system diseases and disorders. … Bradanicline, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7(α7).
Categories: Heterocyclic Compounds, 2-RingSNS-314
go.drugbank.com/drugs/DB06134InvestigationalSNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. … SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.
Categories: Heterocyclic Compounds, 1-RingSynonyms: 1-(3-chlorophenyl)-3-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}urea